Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Brent Vaughan. [LISTEN TIME: 22 minutes]
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 102, "Potential of Gamma Sensory Stimulation in Alzheimer Disease" features an interview with Brent Vaughan, chief executive officer of Cognito Therapeutics, who provided insight on the mechanism of action behind gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with newer therapies and what the company is looking to achieve in a phase 3 trial.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below: